The first patient has been dosed in a Phase 1/2 clinical trial testing MavriX Bio’s experimental gene therapy, MVX-220, in…
Andrea Lobo, PhD
Andrea Lobo holds a PhD in cell biology/neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She has authored multiple research papers in peer-reviewed journals.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Andrea Lobo, PhD
The first patient has been dosed in a Phase 3 trial evaluating the safety and efficacy of GTX-102,…
GTX-102, Ultragenyx’s investigational gene therapy for Angelman syndrome, improved cognition for participants in a Phase 1/2 trial after…
The Foundation for Angelman Syndrome Therapeutics (FAST) has teamed up with the University of Pennsylvania to develop an investigational…
Changes in the levels of gut bacteria — the gut microbiome — are evident in small and larger animal models…